7) Paul Brennan, Angharad M Shore, Mathew Clement, Saman Hewamana, Catrin M Jones, Peter Giles, Christopher Fegan, Christopher Pepper and Ian A Brewis Generation, Investigation and integration of the B-lymphocyte nuclear proteome. Proteomics (in press). 2009.
6) Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, van den Berg HA, Gostick E, Gallagher K, Jones E, Melenhorst JJ, Godkin AJ, Peakman M, Price DA, Sewell AK, Wooldridge L. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods. 2008 Oct 14.
5) Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008 Apr 15;14(8):2484-91.
4) Saman Hewamana, Suhair Alghazal, Thet Thet Lin, Matthew Clement, Chris Jenkins, Monica L Guzman, Craig T. Jordan, Sundar Neelakantan, Peter A Crooks, Alan K Burnett, Guy Pratt, Chris Fegan, Clare Rowntree, Paul Brennan, and Chris Pepper.The NF- B subunit, Rel A, is associated with in vitro survival and clinical disease progression in CLL and represents a promising therapeutic target. Blood. 2008 May 1;111(9):4681-9. Epub 2008 Jan 28.
3) White, P.C., Shore, A.M., Clement, M., Mclaren, J., Soeiro, I. , Lam, E.W-F. & Brennan, P. (2006) Regulation of Cyclin D2 and the Cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene., 15, 2170-80
2) Breslin, E.M., White, P.C., Shore, A.M., Clement, M. & Brennan, P. (2005). LY294002 and Rapamycin co-operate to inhibit T-cell proliferation. Brit. J . Pharm., 144, 791-800
1) Williams, N.M., Preece, A., Morris, D.W., Purlock, G., Bray, N.J., Stephens, M., Noton, N., Williams, H., Clement, M., Dwyer, S., Curran, C., Wilkinson, J., Moskvina, V., Waddington, J. L., Gill. M., Corvin, A. P., Zammit, S., Kirov, G., Owen, M. J. & O`Donovan, M. C. (2004) Identification in independent samples of a novel schizophrenic risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch. Gen. Psychiatry., 61, 336-344
S Hewamana, M Clement, T Lin, C Rowntree, C Fegan, P Brennan and C Pepper
NF-kappaB as a biomarker for prognosis and target for treatment in Chronic Lymphocytic Leukaemia
Blood, Volume 110, Issue 11: 3091Blood (ASH Nov 2007)
S Hewamana, M Clement, T Lin, C Rowntree, C Fegan, P Brennan and C Pepper
NF-kappaB as a biomarker for prognosis and target for treatment in Chronic Lymphocytic Leukaemia
Leukemia & Lymphoma, September 2007; 48 (suppl 1): S25Poster # P 1.21 IW-CLL (2007)
S Hewamana, M Clement, T Lin, C Rowntree, C Fegan, P Brennan and C Pepper
Quantitative and qualitative assessment of constitutive nuclear factor kappa B expression in CLL cells and its relationship with in vitro spontaneous apoptosis
British Journal of Haematology 2007; 137, (Suppl. 1), 1-88
Poster #47 BSH (2007)